UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Sanofi (NASDAQ:SNY) Q4 2023 Earnings Call Transcript February 1, 2024 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head of IR Paul Hudson - CEO Houman Ashrafian - Global Head of R&D Brian Ford - EVP, Head of Specialty Care Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - CFO Conference Call Participants Luisa Hector - Berenberg Jo Walton - UBS Peter Welford - Jefferies Richard Vosser - JPMorgan Grah ...

Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 2023 Booster vaccines 22 Vaccines performance Polio/ Pertussis/Hib €434m +3.4% Influenza €741m -4.0% €20m -76.1% Meningitis and PPH franchises benefited from public order pattern in the quarter Specialty Care Vaccines GenMed RSV Toddler for 2nd season onwards Innovative vaccines for all target populations • Phase 3 start in Q1 2024 PCV (Prevnar) and Rotavirus (Rotateq) data from IQVIA DDD for private doses, and CDC data for public d ...

Sanofi (NASDAQ:SNY) JPMorgan 42nd Annual Healthcare Conference Call January 9, 2024 1:30 PM ET Company Participants Paul Hudson - Chief Executive Officer Jean-Baptiste de Chatillon - Executive Vice President and Chief Financial Officer Houman Ashrafian - Executive Vice President and Head of Research and Development Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Hi, welcome to the Sanofi Presentation at the 42nd JPMorgan Healthcare Conference. I'm Richard Vosser, European Pharma Analys ...

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding ...

Jean-Baptiste de Chatillon Julie, on switches. . Yes. I think that there's still a great path forward for perhaps Cialis, we're a bit more -- can be more transparent about because we can see it clearly after the latest conversations and the market opportunity for both is significant. So as and when we get the updates for share, but I think also they're very important value credit moments in the future of CHC. So I think perhaps that's why you asked it, but that's still very real. . Two, if I may, would revi ...

Press Release Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS(1) decrease of 2.1% at CER • Specialty Care grew 13.5% driven by Dupixent® (€2,847 million, +32.8%) and ALTUVIIIO® more than offsetting the impact of Aubagio® generic competition in the U.S. • Stable Vaccines sales (-0.6%) benefited from strong Beyfortus® launch offsetting lower influenza vaccines sales • General Medicines ...

Jo Walton Apologies for that. I just have two questions, please. I noticed that Dietmar isn't on the Executive Committee just looking at the -- on your website. I wonder if you could tell us when you're going to be in a position to announce the head -- a new permanent head of R&D? And could I just ask related, another R&D-related question. It's a couple of years now since you bought Title IP for the targeted delivery CAR-T, certain cell types? I wonder -- this area still looks to be facing real challenges. ...

Phase II As of June 30, 2023. For collaborations see slide 59. For abbreviations see slide 60. 1. Also known as SAR445229. 2. Also known as SAR443122/DNL758. 3. Also known as SAR441344. 4. Also known as SAR445256. 5. Also known as DNL788. 6. Also known as SP0178. R&D Pipeline – Phase I As of June 30, 2022. For collaborations see slide 59. For abbreviations see slide 60. 1. Also known as KT474. Planned to start Ph2 studies in HS and AD. 3. Also known as KD033. 4. Also known as KD050. 5. Also known as AMX-818 ...

Exhibit 99.1 TABLE OF CONTENTS 1. CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 CONSOLIDATED BALANCE SHEETS – ASSETS 2 CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS’ EQUITY AND LIABILITIES 3 CONSOLIDATED INCOME STATEMENTS 4 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY 6 CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 10 INTRODUCTION 10 A/ Basis of preparation of the half-ye ...